Published: 20 January 2024
Author(s): Mirko Zoncapè, Antonio Liguori, Emmanuel A. Tsochatzis
Issue: May 2024
Section: Review Article

The development and validation of non-invasive fibrosis tests (NITs) has changed clinical practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent liver disease in western countries, with up to a third of the unselected adult population affected. In this article, we review the use of NITs in the diagnosis and staging of MASLD. We discuss their use in the diagnosis of steatosis, steatohepatitis and fibrosis and critically evaluate recently published data.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.